troglitazone has been researched along with Prostatic Neoplasms in 18 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Troglitazone and 15dPGJ2 inhibit growth of prostate and bladder carcinoma cell lines through different mechanisms and the effects of both agents are PPARgamma-independent." | 3.73 | PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. ( Chaffer, CL; Thomas, DM; Thompson, EW; Williams, ED, 2006) |
| "Further, we show that prostate cancer and cell lines do not have intragenic mutations in the PPARgamma gene, although 40% of the informative tumors have hemizygous deletions of this gene." | 2.69 | Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. ( Aiyer, A; Demetri, G; Eng, C; Figg, WD; Kantoff, PW; Kaufman, DS; Kroll, T; Mueller, E; Oh, W; Sarraf, P; Smith, M; Spiegelman, BM; Zhou, XP, 2000) |
| "Tissue from prostate cancer biopsies had decreased GPx3 mRNA and its level was inversely related to the Gleason score." | 1.37 | High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate. ( Furuya, Y; Koike, H; Liu, D; Matsuda, K; Osei-Hwedieh, D; Raghavachari, N; Remaley, AT; Sekine, Y; Suzuki, K, 2011) |
| "Troglitazone is a ligand for the peroxisome proliferator activated receptor gamma (PPARγ) that decreases growth of human prostate cancer cells in vitro and in vivo." | 1.37 | Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism. ( Akinyeke, TO; Stewart, LV, 2011) |
| "Co-treatment of troglitazone with a GSK-3β inhibitor (AR-a014418) or GSK-3β siRNA significantly augmented the inhibitory effect of troglitazone on the NFκB activity and on prostate cancer cell growth inhibition and apoptotic cell death." | 1.37 | Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression. ( Ban, JO; Han, SB; Hong, JT; Kang, KW; Moon, DC; Oh, JH; Son, SM; Song, HS; Song, MJ; Won, D, 2011) |
| "Troglitazone was a widely used antidiabetic drug that activates PPARgamma." | 1.31 | Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. ( Carey, M; Hisatake, JI; Holden, S; Ikezoe, T; Koeffler, HP; Tomoyasu, S, 2000) |
| " Dose-response clonogenic assays of the PC-3 prostate cancer cell line with troglitazone showed an antiproliferative effect (ED50, 3 x 10(-7) M) and other PPARgamma ligands (BRL49653: ED50, 8 x 10(-8) M; 15-deoxy-delta12,14-prostaglandin J2: ED50, 2 x 10(-6) M; ciglitizone: ED50, not reached; indomethacin: ED50, not reached) showed similar effects." | 1.30 | Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. ( Asou, H; Holden, S; Koeffler, HP; Koshizuka, K; Kubota, T; Miyoshi, I; Said, JW; Williamson, EA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reynolds, MR | 1 |
| Clem, BF | 1 |
| Santha, S | 1 |
| Viswakarma, N | 1 |
| Das, S | 1 |
| Rana, A | 1 |
| Rana, B | 1 |
| Nagata, D | 1 |
| Yoshihiro, H | 1 |
| Nakanishi, M | 1 |
| Naruyama, H | 1 |
| Okada, S | 1 |
| Ando, R | 1 |
| Tozawa, K | 1 |
| Kohri, K | 1 |
| Gottfried, E | 1 |
| Rogenhofer, S | 1 |
| Waibel, H | 1 |
| Kunz-Schughart, LA | 1 |
| Reichle, A | 1 |
| Wehrstein, M | 1 |
| Peuker, A | 1 |
| Peter, K | 1 |
| Hartmannsgruber, G | 1 |
| Andreesen, R | 1 |
| Kreutz, M | 1 |
| Zhu, H | 1 |
| Pan, X | 1 |
| Qi, H | 1 |
| Wang, X | 1 |
| Hou, S | 1 |
| Han, B | 1 |
| Liu, Z | 1 |
| Xu, L | 1 |
| Mansour, M | 1 |
| Schwartz, D | 1 |
| Judd, R | 1 |
| Akingbemi, B | 1 |
| Braden, T | 1 |
| Morrison, E | 1 |
| Dennis, J | 1 |
| Bartol, F | 1 |
| Hazi, A | 1 |
| Napier, I | 1 |
| Abdel-Mageed, AB | 1 |
| Sekine, Y | 1 |
| Osei-Hwedieh, D | 1 |
| Matsuda, K | 1 |
| Raghavachari, N | 1 |
| Liu, D | 1 |
| Furuya, Y | 1 |
| Koike, H | 1 |
| Suzuki, K | 1 |
| Remaley, AT | 1 |
| Akinyeke, TO | 1 |
| Stewart, LV | 1 |
| Ban, JO | 1 |
| Oh, JH | 1 |
| Son, SM | 1 |
| Won, D | 1 |
| Song, HS | 1 |
| Han, SB | 1 |
| Moon, DC | 1 |
| Kang, KW | 1 |
| Song, MJ | 1 |
| Hong, JT | 1 |
| Shiau, CW | 1 |
| Yang, CC | 2 |
| Kulp, SK | 1 |
| Chen, KF | 1 |
| Chen, CS | 4 |
| Huang, JW | 1 |
| Yao, CJ | 1 |
| Lai, GM | 1 |
| Chan, CF | 1 |
| Cheng, AL | 1 |
| Yang, YY | 1 |
| Chuang, SE | 1 |
| Chaffer, CL | 1 |
| Thomas, DM | 1 |
| Thompson, EW | 1 |
| Williams, ED | 1 |
| Wang, YC | 1 |
| Wei, S | 1 |
| Lin, LF | 1 |
| Lee, CC | 1 |
| Lin, CC | 1 |
| Kubota, T | 1 |
| Koshizuka, K | 1 |
| Williamson, EA | 1 |
| Asou, H | 1 |
| Said, JW | 1 |
| Holden, S | 2 |
| Miyoshi, I | 1 |
| Koeffler, HP | 2 |
| Mueller, E | 1 |
| Smith, M | 1 |
| Sarraf, P | 1 |
| Kroll, T | 1 |
| Aiyer, A | 1 |
| Kaufman, DS | 1 |
| Oh, W | 1 |
| Demetri, G | 1 |
| Figg, WD | 1 |
| Zhou, XP | 1 |
| Eng, C | 1 |
| Spiegelman, BM | 1 |
| Kantoff, PW | 3 |
| Hisatake, JI | 1 |
| Ikezoe, T | 1 |
| Carey, M | 1 |
| Tomoyasu, S | 1 |
| Tolcher, AW | 1 |
| Kennedy, A | 1 |
| Padley, RJ | 1 |
| Majeed, N | 1 |
| Pollak, M | 1 |
| Smith, MR | 1 |
1 review available for troglitazone and Prostatic Neoplasms
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.
Topics: Antineoplastic Agents; Chromans; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms; Recept | 2002 |
1 trial available for troglitazone and Prostatic Neoplasms
| Article | Year |
|---|---|
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cell Division; Chromans; Humans; Ligands; Male; Midd | 2000 |
16 other studies available for troglitazone and Prostatic Neoplasms
| Article | Year |
|---|---|
Troglitazone suppresses glutamine metabolism through a PPAR-independent mechanism.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromans; Gene Expression Regulation, Neoplastic; G | 2015 |
Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase.
Topics: AMP-Activated Protein Kinases; Apoptosis; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Su | 2015 |
Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromans; Flow Cytom | 2008 |
Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids.
Topics: Cell Line, Tumor; Cell Proliferation; Chromans; Deoxyglucose; Humans; Hydrogen-Ion Concentration; Hy | 2011 |
Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferatio | 2011 |
Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Surviv | 2011 |
High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate.
Topics: Animals; Cell Line; Chromans; Diet, High-Fat; Epithelial Cells; Gene Regulatory Networks; Glutathion | 2011 |
Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromans; Gene E | 2011 |
Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Chromans; Dose-Response R | 2011 |
Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Topics: Animals; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Chromans; Humans; Mal | 2005 |
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Chromans; Cyclin A; | 2006 |
PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Transitional Cell; Caspase 3; Caspase 7; Cas | 2006 |
Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Chromans; Human | 2007 |
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Dif | 1998 |
Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Blotting, Western; Chromans; Dihydrotes | 2000 |
Other novel agents: Rationale and current status as chemopreventive agents.
Topics: Anticarcinogenic Agents; Atrasentan; Chromans; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Rece | 2001 |